Skip to main content
. 2021 Oct 25;11(20):9953–9966. doi: 10.7150/thno.63743

Table 1.

Profile of SLE patients enrolled for exosome proteomics

SLE# Gender Age SLEDAI Duration (year) dsDNA (U/mL) C3 (mg/dL) C4 (mg/dL) WBC (/mm3) PLT (1,000/mm3) HgB (g/dL) Arthritis Nephritis Hepatitis§ Cohort
1 F 40 6 13 53.5 64.8 19.5 9250 402 12.1 1 1 1 1
2 F 21 4 1 62.4 61.6 14.2 4210 317 12.8 1 0 0 1
3 F 27 6 3 11.8 71.1 19.2 8600 252 12.9 1 0 0 1
4 F 20 12 2.5 49.6 99.5 15.0 3670 205 12.2 1 1 0 1
5 F 66 10 0.2 114.0 56.8 6.6 3400 203 10 1 0 1 2
6 F 42 2 0.3 0.0 128.0 33.7 12,000 262 14.1 1 0 1 2

Cohort #1, patients from the Division of Immunology and Rheumatology at Taichung Veterans General Hospital in Taiwan.

Cohort #2, patients from the Division of Immunology and Rheumatology at Taipei Veterans General Hospital in Taiwan.

§, patients with hepatitis during 2018-2020.

F, female; SLEDAI, SLE disease activity index; C3, complement component C3; C4, complement component C4; WBC, white blood cell; PLT, platelet; HgB, haemoglobin.